Dow (DOW) Q4 2024 Earnings Call Transcript

Dow reported flat operating EBITDA of $1.2 billion on a 2% decline in net sales to $10.4 billion, with pricing pressure across all segments offsetting fifth straight quarter of volume growth. Management guided Q1 operating EBITDA to about $1.0 billion, announced $1 billion in annualized cost cuts, a $300 million to $500 million CapEx reduction, and 1,500 job eliminations, while maintaining its dividend priority. The company also advanced portfolio actions, including the $150 million adhesive sale and a pending infrastructure stake sale that could generate up to $3 billion in proceeds.

Analysis

Dow is signaling that the cycle is no longer being managed as a temporary slowdown; it is being re-underwritten around lower structural earnings power in Europe and a heavier reliance on capital discipline. The key second-order effect is that management is effectively trading away optionality in mature regions to preserve the dividend and fund higher-return projects, which should support near-term cash but caps rebound torque if global industrial activity re-accelerates. That matters because the market will likely treat these actions as defensive until it sees evidence that pricing can outpace feedstock inflation rather than merely lag it.

The most interesting implication is competitive, not company-specific: idled European capacity and selective asset reviews reduce regional supply in the weakest part of the global chain, which should gradually improve margins for better-positioned producers with lower energy costs and more flexible portfolios. In practice, that tends to help North American peers with advantaged feedstocks and domestic demand exposure, while keeping pressure on European integrated chemical assets that already face unattractive spread economics. The Macquarie infrastructure stake sale is also a subtle positive for Dow’s equity duration because it monetizes embedded value without fully exiting control, but it does little to solve core cyclicality.

The setup into the next 1-2 quarters is still margin-negative: input costs are rising before price resets fully clear, maintenance is front-loaded, and the tax/cash conversion optics are noisy. But the more important medium-term catalyst is whether the announced cost actions actually show through by year-end; if they do, Dow can defend FCF even in a flat demand tape. If they don’t, dividend-defense narratives become the central overhang and the equity stays trapped in a low-multiple value bucket.

Contrarian view: the market may be over-penalizing the dividend and underpricing the value of self-help. At this valuation, a credible $1B run-rate cost program plus $2.4B-$3.0B of asset proceeds can materially de-risk the balance sheet and buy time for Path2Zero and other growth projects to matter. The bear case remains that Europe is not a trough but a secular bleed; if that proves true, the current restructuring is a bridge, not a fix.

Key Decisions for Investors

• Avoid adding outright long DOW here; wait for proof of second-quarter margin inflection or evidence that price increases are clearing faster than feedstock costs. Near-term risk/reward is still skewed against earnings revisions.
• Pair trade: long LYB / short DOW for 3-6 months. LYB has better leverage to North American feedstock advantages and less Europe drag; DOW is spending management bandwidth on restructuring rather than cyclic upside.
• Buy DOW downside protection via 3-6 month puts or put spreads if the stock rallies on dividend defense. The asymmetry is that any missed cost-savings or weaker cash conversion would quickly pressure the payout narrative.
• Selective long on European gas-price beneficiaries or North American chemical peers with cleaner exposure rather than DOW itself. If European capacity rationalization continues, the first-order winner is the lowest-cost producer, not the distressed incumbent.
• Watch for a tradeable long only after the Macquarie proceeds close and the mid-year Europe review is announced. If the review confirms meaningful closures, the equity could re-rate on lower supply intensity; if not, the catalyst fades.